Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Weighted Average) (2016 - 2026)

Spyre Therapeutics' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $64.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 36.21% year-over-year to $64.1 million; the TTM value through Dec 2025 reached $64.1 million, up 36.21%, while the annual FY2025 figure was $64.1 million, 36.21% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $64.1 million in Q4 2025 per SYRE's latest filing, up from $60.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $73.7 million in Q2 2022 to a low of $166261.0 in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $33.5 million, with a median of $45.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 95.59% in 2024, then soared 36147.79% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $2.6 million in 2021, then grew by 22.56% to $3.2 million in 2022, then soared by 114.0% to $6.9 million in 2023, then soared by 581.85% to $47.0 million in 2024, then surged by 36.21% to $64.1 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Shares Outstanding (Weighted Average) are $64.1 million (Q4 2025), $60.3 million (Q3 2025), and $60.3 million (Q2 2025).